Please check your internet connection and try again.
# Isoxsuprine hydrochloride
## Overview
Isoxsuprine hydrochloride is a non-ergot vasodilator. It acts as a peripheral vasodilator and may have some beta-adrenergic stimulating properties.
## Primary Indications
* Treatment of peripheral vascular disease, including intermittent claudication and Raynaud's disease.
* To improve blood flow in conditions such as cerebrovascular insufficiency.
## Adult Dosing
* The typical dose is 10 mg to 20 mg orally three to four times daily.
* Maximum daily dose is generally considered to be 80 mg. Dosing may be adjusted based on individual patient response and tolerability.
## Pediatric Dosing
* There is no established pediatric dosing for isoxsuprine hydrochloride. Its use in children is not recommended.
## Dose Adjustments
* No specific dose adjustments are typically required for renal or hepatic impairment, but caution is advised, and lower doses may be considered in patients with severe impairment.
## Contraindications
* Hypersensitivity to isoxsuprine hydrochloride.
* Do not administer intravenously.
## Adverse Effects
* Common: Nausea, vomiting, dizziness, weakness, flushing, headache, stomach upset, rash.
* Less common: Hypotension, tachycardia, tremors, nervousness, drowsiness.
## Key Drug Interactions
* **Antihypertensives:** Isoxsuprine may potentiate the effects of antihypertensive medications, leading to additive hypotension.
* **Sympathomimetic agents:** Concomitant use may lead to additive cardiovascular effects (e.g., increased heart rate, blood pressure).
## Monitoring
* Monitor blood pressure and heart rate.
* Assess for improvement in symptoms of peripheral vascular disease.
* Observe for adverse effects.
## Clinical Pearls
* Efficacy in peripheral vascular disease is variable and controversial.
* Administer orally. Do not administer intravenously.
* Patients should be advised to report any adverse effects.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and local protocols for definitive guidance.*
